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Abstract
Doxorubicin (DOX) is a commonly used life-saving antineoplastic agent that also causes dose-dependent
cardiotoxicity. Because ATP is absolutely required to sustain normal cardiac contractile function and because
impaired ATP synthesis through creatine kinase (CK), the primary myocardial energy reserve reaction, may
contribute to contractile dysfunction in heart failure, we hypothesized that impaired CK energy metabolism
contributes to DOX-induced cardiotoxicity. We therefore overexpressed the myofibrillar isoform of CK (CK-M) in the
heart and determined the energetic, contractile and survival effects of CK-M following weekly DOX (5mg/kg)
administration using in vivo31P MRS and 1H MRI. In control animals, in vivo cardiac energetics were reduced at 7
weeks of DOX protocol and this was followed by a mild but significant reduction in left ventricular ejection fraction
(EF) at 8 weeks of DOX, as compared to baseline. At baseline, CK-M overexpression (CK-M-OE) increased rates of
ATP synthesis through cardiac CK (CK flux) but did not affect contractile function. Following DOX however, CK-M-OE
hearts had better preservation of creatine phosphate and higher CK flux and higher EF as compared to control DOX
hearts. Survival after DOX administration was significantly better in CK-M-OE than in control animals (p<0.02). Thus
CK-M-OE attenuates the early decline in myocardial high-energy phosphates and contractile function caused by
chronic DOX administration and increases survival. These findings suggest that CK impairment plays an energetic
and functional role in this DOX-cardiotoxicity model and suggests that metabolic strategies, particularly those
targeting CK, offer an appealing new strategy for limiting DOX-associated cardiotoxicity.
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Introduction
Doxorubicin (DOX) is an antineoplastic agent often used for
treatment of advanced solid tumors and several hematopoietic
malignancies [1,2]. However, DOX’s therapeutic application is
limited in part by dose-dependent adverse effects on cardiac
function [3,4], resulting in heart failure (HF) [5-7]. A 250-601
mg/m2 cumulative dose of DOX has been reported to cause
abnormalities in systolic and diastolic function in 18-36% of
patients [3].
DOX treatment causes several myocardial metabolic and
morphologic changes [8,9] and a number of molecular
mechanisms have been hypothesized to contribute to its
cardiotoxicity [10-13]. Although DOX-induced cardiotoxicity
may be a multi-factorial process, it seems that impaired energy
metabolism may be a critical, common factor [1,2,14-17]. ATP
is absolutely required for normal cardiac contractile function
and DOX reduces the cardiac high-energy phosphates, ATP
and creatine phosphate (PCr), as well as the myocardial
PCr/ATP ratio in experimental models and in people [18-22].
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DOX also inhibits the creatine kinase (CK) reaction, the prime
myocardial energy reserve reaction which rapidly and
reversibly exchanges a phosphoryl group between ATP and
PCr [23-26]. Following chronic DOX administration in a murine
model, myocardial energetic changes, indexed by a reduced
PCr/ATP ratio, occur relatively early and precede the
appearance of contractile dysfunction and predict the
subsequent degree of contractile abnormalities [27],
suggesting, but not proving, a causal role for impaired energy
metabolism in subsequent DOX-induced cardiac dysfunction.
However it is not clear whether the decline in CK metabolism
contributes to DOX-induced cardiac dysfunction or is simply
another consequence of DOX. To determine the role of
impaired CK metabolism in DOX-induced cardiotoxicity, we
studied the consequences of cardiac-specific over-expression
of the myofibrillar isoform of CK (CK-M-OE), the predominant
CK isoform in the adult heart, in mice administered DOX. We
recently reported that CK-M-OE does not alter contractile
function in the normal heart but that in mice with HF induced by
thoracic aortic constriction (TAC), CK-M-OE improves impaired
energetics, contractile function at rest and during adrenergic
stress, and increases survival [28,29]. We therefore exploited
these CK-M-OE mice to address the role of impaired CK
metabolism in DOX cardiotoxicity by exposing them and non-
transgenic littermates to a DOX regimen previously shown to
induce contractile dysfunction [27]. We used non-invasive 31P
magnetic resonance spectroscopy (MRS) to determine the
effect of CK-M-OE on in vivo cardiac energetics (PCr and ATP
levels and the rate of ATP synthesis through CK) and the
subsequent impact on left ventricular function and remodeling
in hearts chronically administered DOX. We also determined
the effect of CK-M overexpression on survival. These
integrated studies were designed to test the hypothesis that
CK-M-OE improves impaired cardiac energetics, contractile
dysfunction, and survival in murine DOX-induced cardiotoxicity.
Methods
Animal Studies
The procedure and protocols were reviewed and approved
by the Institutional Animal Care and Use Committee of the
Johns Hopkins University (#MO10M139). All transgenic mice
development work was performed at the transgenic core facility
of the University of California, Los Angeles (UCLA), USA.
Transgenic mice (CK-M-OE) were developed on the basis of
the Tet-off system [30]. At the first stage, two types of mice
were generated; first, those with a transgene for the regulatory
protein tTA (tetracycline-controlled transactivator) under the
control of α-MHC promoter and second, mice expressing the
CK-M transgene under the control of a tetracycline-responsive
element (TRE) following microinjection of the CK-M construct
into fertilized mouse embryos (C57BL/6 strain) [28]. After the
crossing of TRE-CK-M mice with α-MHCtTA mice, double
transgenic mice (CK-M-tTA) were confirmed by genotyping and
CK-M transgene induction was achieved by switching from a
diet containing doxycycline (650 mg/kg body weight) to a
regular chow diet at least four weeks prior to study (hereafter
called CK-M-OE). Control mice were littermates containing
either the tTA or CK-M transgenes alone or double transgenic
CK-M-tTA mice with the CK-M transgene turned “off” by
maintenance of the doxycycline diet since these three groups
have similar, normal myocardial CK activity [28,29].
CK-M-OE and control adult littermate mice were
administered intra-peritoneal DOX (5mg/kg) once a week for
five weeks. The DOX dosing schedule was adapted from that
previously reported [27]. The cumulative DOX dose was
25mg/kg (or ~180mg/m2). To determine the effect of DOX
administration on lung/body weight ratios, other control and
CK-M-OE animals were sacrificed after five weekly injections of
DOX or an equal volume of saline.
In vivo MRI/MRS studies
All in vivo MRI/MRS experiments were carried out on a
Bruker Biospec MRI/MRS spectrometer equipped with a 4.7T/
40cm Oxford magnet and a 12cm (inner diameter) actively
shielded gradient set, as previously described [28-33].
Specifically, mice were positioned on a Plexiglas platform
housing 22-mm 1H MRI and 13-mm 31P MRS coils and with
temperature control (37±1°C). Anesthesia was induced with
~2% isoflurane in an induction chamber and maintained at ~1%
in 50/50 air/oxygen mixture delivered through a nose cone, as
previously described [28,32,33]. Electrocardiographic (ECG)
and respiratory monitoring were performed continuously during
MRI/MRS experiments. Because some chronically ill DOX-
administered mice do not tolerate prolonged anesthesia, the
functional MRI and energetic MRS studies were performed
separately. Cine MRI experiments were performed at 6 and 8
weeks after DOX administration for left ventricular (LV) function
and morphology in a fashion comparable to an earlier, separate
study [27]. Multi-slice FLASH cine MR images were acquired
(15 frames, TE = 1.5 ms, TR = 7ms, flip angle = 45°) of the
entire LV to assess LV mass, ventricular volumes and ejection
fraction (EF) [28,32,33]. MRIs were analyzed with ImageJ
software. The largest and smallest LV volumes were visually
identified as end-diastolic (EDV) and end-systolic volume
(ESV). LV mass was the sum of all end-diastolic cross-
sectional slices of the LV epicardial and endocardial area
difference multiplied slice thickness and by 1.05 (cardiac
tissue-specific gravity). The LV EF was calculated from the
relative difference in EDV and ESV. A separate 31P MRS
protocol including the Triple Repetition Time Saturation
Transfer (TRiST) method for ATP kinetics was used during the
7th week of DOX administration to measure the rate of ATP
synthesis through CK (CK flux) from the product of [PCr] and
(kf), the CK pseudo-first order rate constant, as previously
described [29,31]. Specifically, localized 31P MR spectra were
obtained with a one-dimensional chemical shift imaging
sequence (16 mm field of view, 16 phase encoding steps)
using modified BIR4 90° adiabatic pulses. Two acquisitions
with different repetition periods (TR=1.5s, NEX=96 and TR=6s,
NEX=32) were acquired in the presence of a saturating
irradiation pulse applied to the exchanging CK moiety, viz., γ-
phosphate of ATP at -2.5 ppm, relative to PCr, and another
acquisition, fully relaxed (TR=10s, NEX=16) in the presence of
control irradiation applied at +2.5ppm relative to PCr. The
measured signal intensities were normalized for different NEX.
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Absolute [PCr] and [ATP] were evaluated in vivo as described
previously [31,34]. Animals that were sacrificed were given
isoflurane anesthesia until a deep level of anesthesia was
obtained, as documented per toe pinch, and then the hearts
were removed.
To determine whether CK-M overexpression improved
survival during DOX administration, a separate study was
performed with CK-M-OE (n=32) and control (n=39) mice which
were followed for 8 weeks after DOX administration (intra-
peritoneal DOX 5mg/kg weekly for 5 weeks for a cumulative
dose of 25mg/kg) with daily cage census. Eight mice (five
controls and three CK-M-OE) were euthanized for humane
reasons once it became clear the mice were terminally ill.
Statistical Analyses
Results are presented as mean ± standard deviation (SD).
Survival curves were generated using the Kaplan-Meier
survival function using statistical XLSTAT. Comparisons of
MRI- and MRS-derived measures of LV anatomy, function and
metabolism among multiple groups were analyzed by one way
ANOVA and significant differences were assessed with the
post hoc Student-Newman-Keuls multiple comparisons test.
Results
At baseline, prior to DOX, control and CK-M-OE mice had
similar body weights (40.0±6.4g vs 42.2±8.4g, respectively, p=
NS). Mice lost weight during DOX administration, as previously
observed, but the mean weight loss was similar in control and
CK-M-OE animals (-12.3±6.0g vs -11.1±6.1g, respectively, p =
NS). Importantly, the mortality after 8 weeks of DOX
administration was ~80% in control mice but only ~56% in CK-
M-OE mice (p<0.02, Figure 1).
Representative cardiac MR images and in vivo 31P MR
spectra are shown in Figures 2 and 3. The images and spectra
were generally of a high-quality, as previously reported in vivo
for mice, and showed that at baseline, CK-M-OE had no effect
Figure 1.  CK-M overexpression improves survival following DOX administration in mice.  Kaplan-Meier survival curves
showing higher survival following DOX in CK-M-OE mice (dotted line n = 32) as compared with control mice (solid line, n = 39). *P
<0.02,.
doi: 10.1371/journal.pone.0074675.g001
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on LV systolic or diastolic volumes, ejection fraction (EF), mass
(Table 1), or cardiac high-energy phosphate levels (Figure 3),
but it did increase the rate of ATP synthesis through CK (CK
flux). These observations are consistent with the original
description of these conditional CK-M overexpressing mice
[28].
Six weeks after starting DOX, LV volumes, EF and mass
were unchanged in control and CK-M-OE mice (Table 1). DOX
impaired in vivo cardiac energetics as documented by 31P MRS
which revealed a significant in vivo reduction in cardiac
PCr/ATP ratio, [PCr], and CK flux in control mice seven weeks
after starting DOX, as compared to baseline values (Figure 3).
In contrast, CK-M-OE prevented the DOX-induced decline in
the in vivo cardiac PCr/ATP ratio, [PCr] and CK flux observed
in control DOX mice (Figure 3).
DOX-associated contractile dysfunction was first detected at
8 weeks in control mice (Table 1). Mean EF and stroke volume
(SV) were modestly but significantly lower in control DOX
hearts than at baseline, while mean cardiac output (CO)
trended lower and end systolic volume (ESV) trended non-
significantly higher (Figure 2 and Table 1). In contrast in CK-M-
OE hearts 8 weeks after starting DOX, EF was unchanged
from baseline and significantly higher (62±3%) than that in
control DOX hearts at the same time (52±7%, p<0.001). In
addition, ESV trended lower and CO trended higher in CK-M-
OE DOX hearts as compared to control DOX-administered
hearts (Table 1).
An increase in the lung/body weight ratio in animal models of
HF is often used to assess pulmonary congestion. Although the
systolic dysfunction was relatively mild, it is interesting to note
that the lung/body weight ratios were significantly increased in
control mice following DOX as compared to those treated with
saline (p<0.001, Table 2) but were not different in CK-M-OE
mice following DOX as compared to CK-M-OE administered
saline (p=0.12, Table 2). Nevertheless, the lung/body weight
ratios were similar in control and CK-M-OE mice. In summary,
DOX depressed cardiac high-energy phosphates, CK flux and
left ventricular EF in control hearts as compared to baseline
Figure 2.  In vivo MRI reveals murine cardiac morphologic and functional changes after DOX.  Typical transverse short-axis in
vivo1H MR images of the mid-left ventricle at end-systole and end-diastole at baseline (top row), 6 weeks (middle row) and 8 weeks
(bottom row) in control (left panel) and CK-M-OE (right panel) mice. LV= left ventricle, RV= right ventricle, P= spherical fiducial
phantom embedded in MR surface coil outside of the mouse body.
doi: 10.1371/journal.pone.0074675.g002
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Figure 3.  In vivo measures of myocardial energetics in DOX administered mouse hearts were obtained with noninvasive
31P MRS.  (A) Typical transverse 1H MR image of a mouse at the mid-left ventricle withthe location of 31P MR cardiac voxel denoted
between the white lines. (B) 31P MR spectrum with control saturation and TR=10s and NEX=16. (C) Spectrum with γ-phosphate of
ATP saturated with TR = 6 s, NEX = 32. (D) Spectrum with γ-phosphate of ATPsaturation and TR=1.5s, NEX=96. β-ATP; β-
phosphate of ATP. (E–I) Summary of in vivo energetics (mean+SD) for control (gray bars, n = 11), control with DOX (whitebars, n =
5), CK-M-OE (bars with dotted background, n = 8), and CK-M-OE with DOX (black bars, n = 5) mice. (E) Cardiac PCr/ATP. (F) PCr
concentration (µmol/g wet weight). (G) ATP concentration (µmol/g wet weight). (H) CK pseudo-first-order rate constant (kf, s-1). (I)
ATP synthesis rate through CK (CK flux, μmol/g/s). **P < 0.01, ***P < 0.001.
doi: 10.1371/journal.pone.0074675.g003
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(Table 1). CK-M-OE improved depressed energetics in DOX
hearts and this was associated with significantly better EF and
trending better CO and ESV at 8 weeks, along with an
attenuation of the development of pulmonary congestion.
To determine whether these early metabolic and functional
changes were associated with histopathologic changes of DOX
cardiotoxicity, electron micrographs were obtained eight weeks
after initiation of DOX or placebo. In DOX-administered hearts,
there was patchy, very mild vacuolization with minimal
myofibrillar loss as compared to saline-treated hearts (Figure
4). However there were no dramatic ultrastructural differences
between control DOX and CK-M-OE DOX hearts, and none of
the hearts showed severe degenerative changes.
Discussion
There are several main findings from this in vivo study of
augmented CK energy metabolism in DOX cardiotoxicity. First,
we observe that not only is cardiac PCr/ATP reduced with
DOX, as previously reported [35], but that for the first time that
the absolute concentration of [PCr] and the in vivo rate of ATP
synthesis through CK (CK flux) are significantly reduced
following chronic DOX administration in control hearts. Second,
CK-M overexpression increases the rate of CK flux in placebo-
treated hearts but has no effect on PCr/ATP, [PCr] and [ATP]
Figure 3) or on contractile function (Table 1), consistent with a
prior report [28]. Third, critically, CK-M overexpression prevents
the early decline in cardiac high-energy phosphates in DOX
mice and attenuates the subsequent contractile dysfunction
Table 2. Lung/body weight ratios: lung (mg)/body weight (g)
at 8 weeks are shown for control and CK-M-OE mice.
 Saline DOX
Control 3.6±0.6 5.0±0.3*
CK-M-OE 4.4±1.0 5.2±0.6
Mean±SD, n=6-10 for each group *p<0.001 vs control
doi: 10.1371/journal.pone.0074675.t002
observed following DOX. Fourth, CK-M overexpression does
not appear to alter the early mild ultrastructural changes
associated with DOX cardiotoxicity. Fifth, CK-M over-
expression increases survival following DOX. These findings
demonstrate the DOX-induced depression of cardiac CK-
related energy metabolism contributes, at least in part, to the
early contractile dysfunction and reduced survival with DOX
cardiotoxicity in this model.
Although DOX is an extremely effective antineoplastic drug,
the cumulative dose of DOX that can be administered is often
limited by cardiotoxicity [1,2]. A number of potential
mechanisms of DOX cardiotoxicity have been identified [36-38]
but no accepted, evidence-based means to prevent DOX
cardiotoxicity is currently available [39]. Because of the prior
evidence pointing to DOX-induced mitochondrial and energetic
abnormalities, the focus of this work was on the effect of
augmented CK energy metabolism on contractile function and
survival following DOX.
DOX consistently reduces myocardial high-energy
phosphates and energy metabolism across models and
species. In isolated myocytes, DOX reduces high-energy
phosphates by 30% or more in many studies [2]. In isolated
perfused hearts DOX lowers cardiac PCr and ATP acutely
[22,40] and, in hearts previously administered DOX on a
chronic basis, the high-energy phosphate reductions were even
larger [19]. In vivo cardiac PCr/ATP declines after chronic DOX
administration and the decline precedes contractile
abnormalities and predicts eventual mechanical dysfunction
[27]. The current in vivo findings extend those prior
observations of an early decline of in vivo cardiac PCr/ATP and
demonstrate here that CK ATP kinetics (both CK kf and CK
flux) are also reduced early after DOX and are not merely a
late consequence in end-stage cardiotoxicity.
There are several mechanisms that likely contribute to the
altered cardiac energetics in DOX cardiotoxicity. Oxidative
stress (OS) is the most commonly described mechanism for
DOX induced cardiotoxicity [41-44] and this contributes to
mitochondrial swelling, apoptosis and eventual myofibrillar loss.
Myocellular loss with fibrotic replacement, if present, could
potentially explain some high-energy phosphate loss
Table 1. LV morphology and function by MRI in DOX-treated control and CK-M-OE mice.
  HR, bpm EDV, µl ESV, µl SV, µl EF, % CO, ml/min LVmass, mg
Control (n=6)  418±20  65.4±8.8  22.0±4  43.4±4  66.5±2  18.1±1  104±8
Control DOX (6wk) (n=10)  432±46  72.9±13  29.4±8  43.4±5  60.1±4  18.7±3  100±17
Control DOX (8wk) (n=8)  435±47  72.0±19  36.1±16  35.9±3b  51.7±7a,c,d,e  15.6±2  101±18
CK-M-OE (n=6)  440±20  69.1±8.8  23.2±4.6  46.0±4  66.7±3  20.2±1  105±3
CK-M-OE DOX (6wk) (n=7)  454±56  66.5±10  25.7±7  40.8±4  61.8±5  18.5±2  98±10
CK-M-OE DOX (8wk) (n=7)  473±12  63.0±13  24.1±6  38.9±7  61.8±3  18.3±3  103±18
Values are means ±SD;n, number of mice. HR, heart rate; EDV, end-diastolic volume; ESV, end-systolic volume; SV, stroke volume; EF, ejection fraction;CO, cardiac
output, LV, left ventricular.
a p<0.001 compared to control
b p<0.05, c p<0.01 compared to DOX treated control (6wk)
d p<0.01 compared to DOX treated CK-M-OE (6wk),
e p<0.01 compared to DOX treated CK-M-OE (8wk)
doi: 10.1371/journal.pone.0074675.t001
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Figure 4.  Mild ultrastructural changes are observed in this
DOX model.  Electron micrograph obtained 8 weeks after
randomization to placebo (top panel) or to DOXfrom control
(middle panel) and CK-M-OE (bottom panel) indicating mild,
patchy myofibrillar loss in DOX hearts.
doi: 10.1371/journal.pone.0074675.g004
(measured as µmol/g tissue) observed here, although we did
not observe significant degenerative loss or fibrosis (Figure 4).
Mitochondrial dysfunction and uncoupling induced by DOX
along with direct effects on the energy sensor AMP-activated
protein kinase (AMPK) [45], could also limit ATP production
along with DOX-impairment of fatty acid and glucose
metabolism [1]. The DOX-induced reduction in CK flux is likely
not due to myocyte loss alone since the former (~50%) is out of
proportion to the latter and ATP levels are normal. OS and
DOX, individually and together, have been shown to impair the
structure and function of both the myofibrillar and mitochondrial
isoforms of CK [2,46-48]. Oxidative CK injury is further
exacerbated in the presence of ferrous iron [49]. A sub-fraction
of cytosolic CK enzymes are associated with ATP utilizing sites
(actomyosin ATPase and SR Ca2+ATPase) and the
peroxynitrite-related protein nitration that occurs in DOX
cardiotoxicity specifically interferes with myofibrillar CK-M
[26,50]. The mitochondrial CK isoform is also susceptible to
DOX-induced OS injury with resulting dimerization, reduced
activity, impaired binding to cardiolipin and reduced channeling
of high-energy phosphates from the mitochondria to the
cystosol [1,51]. Thus several well-established factors likely
contribute to cardiac energetic abnormalities that occur
relatively soon after DOX administration. Cardiac-specific
conditional CK-M overexpression was able to augment the
reduced cardiac CK flux in DOX hearts back to CK ATP
synthesis rates of control, saline-treated hearts (Figure 3).
Antioxidant and other approaches designed to limit OS and CK
injury following DOX would have been reasonable alternative
approaches [52], but the “brute-force” CK-M overexpression
strategy used here was specific for CK-M and effective in
normalizing myofibrillar CK ATP delivery rates in DOX hearts.
CK-M overexpression normalized cardiac CK flux and [PCr]
in DOX hearts and improved their depressed mean left
ventricular ejection fractions, suggesting that the early
contractile dysfunction in DOX-cardiotoxicity is related, at least
in part, to insufficient myofibrillar energy delivery. In a prior
study of TAC-induced left ventricular hypertrophy and heart
failure, CK-M overexpression increased cardiac high-energy
phosphates and attenuated the depressed contractile function
resulting from TAC [28]. The contractile benefit resolved when
the CK-M overexpression was withdrawn by manipulation of
the CK-M transgene while in animals in which CK-M
overexpression was maintained survival was significantly better
after TAC as compare to littermates. Those results suggest that
inadequate energy supply underlies, at least in part, contractile
dysfunction in heart failure [28]. The current findings of
improved contractile function and survival after DOX are
consistent with the prior report in TAC and indicate in at least
two murine models of contractile dysfunction, TAC-induced
heart failure and DOX-cardiotoxicity, that inadequate energy
supply contributes to mechanical dysfunction or that the
dysfunctional, failing heart is energy starved as it relates to CK
metabolism.
A potential criticism of this study is that the focus was on the
early contractile dysfunction of DOX-cardiotoxicity rather than
on end-stage heart failure. The early time was chosen for two
reasons. First, contractile function is followed clinically in DOX-
Creatine Kinase in Doxorubicin Cardiac Dysfunction
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treated patients such that if an early decline in ejection fraction
is noted, DOX dosing can be held or limited in the hope of
avoiding irreversible injury and subsequent heart failure. Thus
the early dysfunction has some clinical relevance. Second, late
or end-stage DOX cardiotoxicity is associated with irreversible
myocellular and myofibrillar loss. Augmentation of metabolic
energy reserve in surviving myocytes is unlikely to affect
function following irreversible injury with apotosis and necrosis.
Thus the early stages of DOX cardiotoxicity offered a clinically
based model, unlike myocardial infarction with necrosis, to
evaluate the role of energy starvation in dysfunctional or failing
hearts without dense necrosis and cellular loss. Because of the
negative impact of DOX on mitochondrial CK, it would be of
interest to determine whether over-expression of the
mitochondrial CK isoform would also improve contractile
dysfunction.
In summary, CK-M-OE increases depressed cardiac high-
energy phosphate levels and rates of ATP synthesis through
CK, the primary energy reserve reaction, following DOX
administration and this is associated with a significant
improvement in left ventricular EF and in survival in DOX
animals. These findings indicate that the contractile dysfunction
occurring early after chronic DOX administration is related, at
least in part, to inadequate myofibrillar energy supply and
suggest that strategies that improve myocardial metabolism or
limit energetic decline may provide an important new avenue in
limiting the consequences of DOX-cardiotoxicity and thereby
extending its therapeutic impact.
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